Massana 1999.

Methods	Six‐week randomised, double‐blind, multicentre study
Participants	In‐ and outpatients fulfilling DSM‐III‐R criteria for depressive episode (lasting between 1 to 8 months), without psychotic features, with a score of at least 22 on the Hamilton Rating Scale for Depression (HDRS). Age range: 18‐65 years Exclusion criteria: pregnancy, absence of contraception, dysthymia/cyclothymia, substance abuse disorder, high risk of suicide, resistance to antidepressant treatment, history of major depressive disorder associated with endocrine disorder and/or drug hypersensitivity, chronic respiratory insufficiency, a history of seizures or brain injury, a history or current evidence of any other important clinical condition or use of electroconvulsive therapy in the previous 6 months.
Interventions	Fluoxetine: 89 participants Reboxetine: 79 participants Fluoxetine dose range: 20‐40 mg/day Reboxetine dose range: 8‐10 mg/day Chloral hydrate (0.5‐1 mg) for sleep
Outcomes	Primary outcome: change in the HDRS total score, number of patients showing response (decrease of at least 50% in HDRS total score) and remission (a final score of 10 or less) Seconday outcomes: Clinical Global Impression‐Severity (CGI‐S), Montgomery and Asberg Scale for Depression (MADRS), Patient Global Impression (PGI)
Notes	Funding: unclear
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further information
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double blind, no further information
Incomplete outcome data (attrition bias) All outcomes	High risk	Number of withdrawals reported, but reasons for dropout not clearly described. Scores reported without denominator
Selective reporting (reporting bias)	Unclear risk	SIde effects not clearly reported. Mean endpoint scores reported with standard deviation
Other bias	Unclear risk	Funding: unclear